Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses the rationale behind the phase 2 RETAIN 1 trial, aimed at evaluating how muscle-invasive bladder cancer is treated. The RETAIN trial explores whether certain patients can safely avoid invasive procedures such as radical surgery or chemoradiation and retain their bladders without compromising long-term outcomes. ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
The final segment of this roundtable series addresses the future of immunotherapy combinations.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Advertisement
Section Editor
Brad McGregor, MDGenitourinary Medical Oncologist | Dana-Farber Cancer Institute
Advertisement
Get the latest bladder cancer research straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.